Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics

Jun 09, 2016, 08:40 ET from Chelmsford Park SA

NEW YORK, June 9, 2016 /PRNewswire/ --

On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:

BioMarin Pharmaceutical Inc.'s stock lost 1.64% to close the day at $84.10 with a total volume of 1.03 million shares traded. The Company develops and commercializes pharmaceuticals for serious diseases and medical conditions in the U.S., Europe, Latin America, and internationally. The Company's shares have advanced 0.14% in the last one month. The stock is trading 2.30% below its 50-day moving average. Additionally, BioMarin Pharmaceutical's stock has a Relative Strength Index (RSI) of 45.95. Sign up and read the free notes on BMRN at:

On Wednesday, shares in New Haven, Connecticut headquartered biopharma Company, Alexion Pharmaceuticals Inc., ended the session 0.54% higher at $138.88 with a total volume of 2.95 million shares traded. Shares of the Company traded at a PE ratio of 193.43. The stock is trading 5.73% below its 50-day moving average. Moreover, shares of Alexion Pharmaceuticals have an RSI of 41.35. The complimentary notes on ALXN can be downloaded in PDF format at:

Cambridge, Massachusetts headquartered biopharma Company, Aegerion Pharmaceuticals Inc.'s stock finished Wednesday's session 4.76% lower at $1.60 with a total volume of 757,956 shares traded. The stock is trading below its 50-day moving average by 39.28%. Aegerion Pharmaceuticals' stock has an RSI of 35.12. Register for free on and access the latest research on AEGR at:

On Wednesday, shares in Acorda Therapeutics Inc. ended the day 1.17% lower at $27.93 with a total volume of 460,939 shares traded. Shares of the Company traded at a PE ratio of 89.81. The Company's shares have advanced 2.95% in the last one month. The stock is trading above its 50-day moving average by 1.68%. Furthermore, shares of Acorda Therapeutics have an RSI of 52.25. The Company was founded in 1995 and is headquartered in Ardsley, New York. Get free access to your trade alert on ACOR at:


Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA